Begin typing your search above and press return to search.
Volume: 19 Issue: 4 April 2021

FULL TEXT

CASE REPORT
Kidney Transplant and Autosomal Recessive Polycystic Disease: A Case Report and Literature Review of 2 Brothers

Abstract

Autosomal recessive polycystic disease is a rare hepatorenal disorder. End-stage renal disease and liver fibrosis are serious presentations of this disease. Here, we report 2 brothers with autosomal recessive polycystic disease who presented with abnormal abdominal protrusion and hepatosplenomegaly during infancy and eventually underwent renal transplant. Congenital hepatic fibrosis and nephromegaly followed by renal failure developed, after which renal transplant was successfully performed. The remaining compli­cation after transplant was hematemesis and melena due to esophageal varices. Autosomal recessive polycystic disease has a broad spectrum of symptoms; similar pre­sentations with manifestations in siblings may explain some unknown genetic causes of this rare disease.


Key words : End-stage renal failure, Liver fibrosis, Renal transplant

Introduction

There are few known congenital disorders that present with hepatorenal involvement, and autosomal recessive polycystic disease (ARPKD) is one of these congenital disorders. Autosomal recessive polycystic disease has a prevalence of 1 in 20 000 births. It is defined by the association of renal (enlarged microcytic kidneys) and liver (congenital hepatic fibrosis, portal hypertension, Caroli disease) manifestations, which are caused by mutations in the PKHD1 gene that maps in the short arm of chromosome six.1,2

Approximately 40% of patients die in infancy due to respiratory failure.3 In older children, the most frequent signs are hypertension and liver enlargement. Hypertension is seen in about 50% of patients, which causes the need to take antihypertensive drugs. Renal insufficiency will develop after infancy, and the patient will require dialysis and renal transplant.4 It has been illus­trated that at least 1 missense mutation is critical for surviving during the neonatal period.5 Here, we pre­sent a familial hepatorenal disease in 2 brothers who both eventually received successful renal transplant.

Case Report

The patients were 2 brothers (27 and 21 years old) who presented with abnormal abdominal protrusion du­ring infancy. In their ultrasonograph evaluations, spleno­megaly was revealed during year 1 without convincing reason. Splenic arterial embolization was performed by an expert interventional radiologist, resulting in re­duced spleen size within 3 months. The only hematolo­gic problem was minor thalassemia in the older brother, which could not explain the spleen enlargement, with only mild anemia (hemoglobin level of 9 g/dL).

In addition, hepatomegaly was detected in sonograph reports during the second year of life, and congenital hepatic fibrosis was detected in liver biopsies. Liver function tests were normal except for mildly increased direct bilirubin level in the older brother (1.5 mg/dL). Both patients did not present with gastrointestinal symptoms until the second decades of life, at which time dyspepsia and epigastric pain developed. Symptoms were exacerbated in both brothers, with both eventually having several episodes of upper gastrointestinal bleeding due to esophageal varices. These complications led to variceal ligation.

The presentation of kidney problems occurred in year 4 of life with renal enlargement. However, renal function abnormality was only shown at age 20 years, with increased serum creatinine level to 5 mg/dL and sudden onset of hypertension. Over the course of less than 1 year, rapid progressive renal impairment occurred and renal size decreased dramatically, with color Doppler sonography demonstrating arterial stenosis. Hemodialysis was started for both patients (mean time of dialysis of 5.5 months). Both patients received deceased donor renal transplant procedures (in 2014 and 2017 for the older and the younger brother, respectively). Both transplant procedures were successful with normal creatinine levels (1.2 and 1.1 mg/dL for the older and the younger brother, respectively) and liver compensation. The only remaining complication was esophageal varices, which caused hematemesis and melena.

Discussion

There are many syndromes that have different organ involvement. Renal failure in addition to hepatic fibrosis has been found in some of these syndromes. In this report, we presented 2 brothers (non-twin) who both had the same presentation of ARPKD.

Autosomal recessive polycystic disease is a genetic disease that presents with renal failure, congenital hepatic fibrosis, and pancreatic cyst and fibrosis.1 The characteristics of ARPKD patients in the relevant literature are shown in Table 1.

The onset of symptoms has a wide range of presentation, according to age. It has been categorized into 3 groups: <1 year, 1 to 20 years, and >20 years old.6 In our case report, both brothers had symptoms that started at age 1 with abnormal abdominal protrusion.

Splenomegaly is diagnosed in 38% to 71% of patients with ARPKD. It usually presents in infancy and is managed according to severity of disease. Splenectomy is the most reported surgical treatment for patients.2,3,7 Similar to previous studies, in our cases, splenomegaly was seen in infancy, which was managed successfully with angioembo­lization.

Liver involvement is the other manifestation of ARPKD; pathologically, congenital hepatic fibrosis is considered as a pathognomonic involvement of liver in ARPKD. The fact that congenital hepatic fibrosis is part of the nature of this disease is debatable.8,9 Furthermore, portal area fibrosis, hypoplasia of portal vein, and intrahepatic bile duct ectasia (Caroli disease) are the other pathological findings. Although hepatomegaly, arterial hypertension, and intrahepatic biliary dysgenesis may occur in infancy, variceal bleeding and portal hypertension, which are more serious presentations of liver involvement, are later presentations of ARPKD.6,10 Moreover, combined renal/hepatic transplant has been reported in some patients.7 In our patients, although liver pathology in the second year of life revealed congenital hepatic fibrosis and the patients developed upper gastro­intestinal bleeding by adolescence, the liver was not yet compensated, which obviated the need of more aggressive treatment for liver involvement.

In ARPKD patients, the early manifestation of kidney involvement in childhood is usually renal enlargement, which may be followed by rickets, acidosis, and eventually renal failure. All patients who survive are candidates for hemodialysis and probable renal transplant in adulthood. Renal appearance in ultrasonographic examinations during infancy includes nephromegaly and normal or loss of cortico-medullary differentiation, which would change to renal cyst and tubular ectasis in early adulthood, with eventual decreasing renal size in most patients.2,3,7,10,11 In our patients, the sonographic findings and progression of disease were similar to those shown in previous studies. As of today, both of our patients have had no new complaints and renal function tests have been normal. Their livers compensate, with the remaining problem being esophageal varices that will need ligation.

Conclusions

Clinical severity of ARPKD depends on suspected germline mutations. According to our observations of similar progression of disease and treatment, timely diagnosis and genetic antenatal counseling, precise management of infantile and childhood manifestations, and the right decision for adulthood complications of renal and liver involvement may increase the life expectancy of patients.


References:

  1. Jiang L, Fang P, Weemhoff JL, Apte U, Pritchard MT. Evidence for a “Pathogenic Triumvirate” in congenital hepatic fibrosis in autosomal recessive polycystic kidney disease. Biomed Res Int. 2016;2016:4918798. doi:10.1155/2016/4918798
    CrossRef - PubMed
  2. Al Alawi I, Molinari E, Al Salmi I, Al Rahbi F, Al Mawali A, Sayer JA. Clinical and genetic characteristics of autosomal recessive polycystic kidney disease in Oman. BMC Nephrol. 2020;21(1):347. doi:10.1186/s12882-020-02013-2.
    CrossRef - PubMed
  3. Bergmann C, Senderek J, Windelen E, et al. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int. 2005;67(3):829-948. doi:10.1111/j.1523-1755.2005.00148.x
    CrossRef - PubMed
  4. Capisonda R, Phan V, Traubuci J, Daneman A, Balfe JW, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: outcomes from a single-center experience. Pediatr Nephrol. 2003;18(2):119-126. doi:10.1007/s00467-002-1021-0.
    CrossRef - PubMed
  5. Ebner K, Dafinger C, Ortiz-Bruechle N, et al. Challenges in establishing genotype–phenotype correlations in ARPKD: case report on a toddler with two severe PKHD1 mutations. Pediatr Nephrol. 2017;32(7):1269-1273. doi:10.1007/s00467-017-3648-x
    CrossRef - PubMed
  6. Adeva M, El-Youssef M, Rossetti S, et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore). 2006;85(1):1-21. doi:10.1097/01.md.0000200165.90373.9a
    CrossRef - PubMed
  7. Chapal M, Debout A, Dufay A, et al. Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study. Nephrol Dial Transplant. 2012;27(5):2083-8. doi:10.1093/ndt/gfr588
    CrossRef - PubMed
  8. Desmet VJ. Congenital diseases of intrahepatic bile ducts: variations on the theme “ductal plate malformation”. Hepatology. 1992;16(4):1069-1083. doi:10.1002/hep.1840160434
    CrossRef - PubMed
  9. Jørgensen M. A stereological study of intrahepatic bile ducts: 4. Congenital hepatic fibrosis. Acta Pathol Microbiol Scand A. 1974;82(1):21-29.
    CrossRef - PubMed
  10. Shenoy P, Zaki SA, Shanbag P, Bhongade S. Caroli's syndrome with autosomal recessive polycystic kidney disease. Saudi J Kidney Dis Transpl. 2014;25(4):840-843. doi:10.4103/1319-2442.135176
    CrossRef - PubMed
  11. Nicolau C, Torra R, Badenas C, et al. Sonographic pattern of recessive polycystic kidney disease in young adults. Differences from the dominant form. Nephrol Dial Transplant. 2000;15(9):1373-1378. doi:10.1093/ndt/15.9.1373
    CrossRef - PubMed
  12. Bolaji O, Erinomo O, Adebara O, et al. Autosomal recessive polycystic kidney disease (ARPKD) in a Nigerian newborn: a case report. Pan Afr Med J. 2018;30:172. doi:10.11604/pamj.2018.30.172.15202
    CrossRef - PubMed
  13. Beil S, Drube J, Gluer S, Lehner F, Ehrich JH, Pape L. End?stage renal disease due to ARPKD in the first months of life: Transplantation or dialysis?–Two case reports. Pediatr Transplant. 2010;14(6):E75-E78. doi:10.1111/j.1399-3046.2009.01167.x
    CrossRef - PubMed
  14. Deget F, Rudnik?Schöneborn S, Zerres K. Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: a clinical comparison of 20 sibships. Clin Genet. 1995;47(5):248-253. doi:10.1111/j.1399-0004.1995.tb04305.x
    CrossRef - PubMed
  15. Zerres K, Rudnik?Schöneborn S, Deget F, et al. Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Acta Paediatr. 1996;85(4):437-445. doi:10.1111/j.1651-2227.1996.tb14056.x
    CrossRef - PubMed


Volume : 19
Issue : 4
Pages : 378 - 381
DOI : 10.6002/ect.2020.0375


PDF VIEW [118] KB.
FULL PDF VIEW

From the 1Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; and the 2Endourology Ward, Urology Department, Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Acknowledgements: The Vice-Chancellery of Research and Technology of Shiraz University of Medical Sciences financially supported this study. The authors declare that they have no conflicts of interest to report.
Corresponding author: Leila Malekmakan, Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, 7193635899 Khalili Street, Mollasdra Avenue, Shiraz, Iran
Phone: +98 711 2127300         
E-mail: malekmakan_l@yahoo.com